Abstract

High expression of programmed death-ligand-1 (PD-L1) in hepatocellular carcinoma (HCC) cells usually inhibits the proliferation and functions of T cells, leading to immune suppression in tumor microenvironment. However, very little has been described regarding the mechanism of PD-L1 overexpression in HCC cells. In the present study, we found epidermal growth factor (EGF) stimulation promoted the expression of PD-L1 mRNA and protein in HCC cells. Inhibition of epidermal growth factor receptor (EGFR) could reverse EGF-induced the expression of PD-L1 mRNA and protein. Subsequently, we also observed that the phosphorylation level of Pyruvate kinase isoform M2 (PKM2) at Ser37 site was also increased in response to EGF stimulation. Expression of a phosphorylation-mimic PKM2 S37D mutant stimulated PD-L1 expression as well as H3-Thr11 phosphorylation in HCC cells, while inhibition of PKM2 significantly blocked EGF-induced PD-L1 expression and H3-Thr11 phosphorylation. Furthermore, mutation of Thr11 of histone H3 into alanine abrogated EGF-induced mRNA and protein expression of PD-L1, Chromatin immunoprecipitation (ChIP) assay also suggested that EGF treatment resulted in enhanced H3-Thr11 phosphorylation at the PD-L1 promoter. In a diethylnitrosamine (DEN)-induced rat model of HCC, we found that the expression of phosphorylated EGFR, PKM2 nuclear expression, H3-Thr11 phosphorylation as well as PD-L1 mRNA and protein was higher in the livers than that in normal rat livers. Taken together, our study suggested that PKM2-dependent histone H3-Thr11 phosphorylation was crucial for EGF-induced PD-L1 expression at transcriptional level in HCC. These findings may provide an alternative target for the treatment of hepatocellular carcinoma.

Highlights

  • Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high mortality rate (Du et al, 2016; Nie et al, 2018)

  • Through real time PCR, we found that epidermal growth factor (EGF) promoted the mRNA expression of programmed death-ligand-1 (PD-L1) in these cancer cells (Figure 1A)

  • To investigate whether EGF-induced H3 Thr11 phosphorylation depended on Pyruvate kinase isoform M2 (PKM2), we examined the effects of epidermal growth factor receptor (EGFR) inhibitor Gefitinib and PKM2 inhibitor shikonin on EGF-induced H3 Thr11 phosphorylation

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high mortality rate (Du et al, 2016; Nie et al, 2018). Numerous studies have showed that EGF/EGFR signal could increase PD-L1 expressions in non-small-cell lung cancer, colon cancer stem cells, renal cancer cells and glioblastoma (Li et al, 2018b; Chen et al, 2019b; Ma et al, 2020; Su et al, 2020). This raise the possibility that EGF/EGFR signal is attributable to the upregulation of PD-L1 in HCC

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call